Virtual Meetings 2023

Meet The Professor: Optimizing the Management of ER-Positive and Triple-Negative Breast Cancer

For an up-to-date schedule of upcoming sessions in this series, please click here.

PARTICIPATING FACULTY

Komal Jhaveri, MD
Associate Attending Physician
Breast Medicine Service and Early Drug Development Service
Section Head, Endocrine Therapy Research Program
Clinical Director, Early Drug Development Service
Department of Medicine
Memorial Sloan Kettering Cancer Center
Assistant Professor of Medicine
Weill Cornell College of Medicine
New York, New York



Additional faculty to be announced.

SERIES MODERATOR
Neil Love, MD
Research To Practice

These activities are supported by educational grants from AstraZeneca Pharmaceuticals LP, Exact Sciences Corporation, Sanofi, and TerSera Therapeutics LLC.

Agenda

Each 1-hour session will be divided into topic modules focused on current management, emerging research and novel agents and strategies under active investigation for breast cancer. Each event will employ an identical format that will include the following elements:

  • Moderator Dr Neil Love and a featured participating clinical investigator
  • Discussion of participating faculty treatment recommendations
  • Review of available clinical research findings
  • Community oncologist video case presentations
  • Interactive audience polling and extensive Q&A

    MODULE 1: Current Approaches to Treatment Decision-Making for Patients with ER-Positive Localized Breast Cancer

    MODULE 2: Integration of Novel Therapies into the Care of Patients with Localized Triple-Negative Breast Cancer (TNBC)

    MODULE 3: Current and Future Treatment Considerations for ER-Positive Metastatic Breast Cancer

    MODULE 4: Selection and Sequencing of Therapy for Metastatic TNBC

Target Audience
This program is intended for medical oncologists, hematologists, hematology-oncology fellows, breast surgeons, radiation oncologists, oncology nurses and other allied healthcare professionals involved in the treatment of breast cancer.

Learning Objectives

  • Evaluate the results of genomic assays and other patient- and treatment-related factors to personalize the use of adjuvant systemic therapy for patients with newly diagnosed ER-positive, HER2-negative breast cancer.
  • Comprehend available findings with CDK4/6 inhibitors for localized ER-positive, HER2-negative breast cancer, and assess the current role of these agents as a component of adjuvant treatment.
  • Consider available research evaluating anti-PD-1/PD-L1 antibody-based approaches for localized triple-negative breast cancer (TNBC).
  • Appraise published efficacy and safety data with PARP inhibitors for patients with localized and metastatic breast cancer (mBC) harboring BRCA1/2 mutations.
  • Review available research with the use of commercially available CDK4/6 inhibitors for the treatment of ER-positive mBC, and optimally incorporate these agents into patient care.
  • Recognize the frequency of PI3K pathway mutations in ER-positive mBC, and employ evidence-based approaches designed to target these aberrations for patients with ER-positive, PIK3CA-mutated disease.
  • Understand available data supporting the use of chemotherapy in combination with anti-PD-1/PD-L1 antibodies for newly diagnosed PD-L1-positive metastatic TNBC, and use this information to identify patients who may be appropriate for this approach.
  • Incorporate published research in the selection and sequencing of available therapeutic agents for patients with PD-L1-negative TNBC or those who experience disease progression on front-line chemoimmunotherapy.
  • Appreciate the clinical relevance of HER2-low breast cancer, and understand available and emerging management approaches for this subset of the disease.
  • Assess early data with and ongoing clinical trials evaluating novel agents and treatment strategies under development for ER-positive and triple-negative breast cancer.

CE Credit
CME and ABIM MOC credit form links will be emailed to each participant within 5 business days of the activity.

Accreditation Statement
Research To Practice is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

Credit Designation Statement
Research To Practice designates each live activity for a maximum of 1 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

American Board of Internal Medicine (ABIM) — Maintenance of Certification (MOC)
Successful completion of each CME activity, which includes participation in the evaluation component and a short post-test, enables the participant to earn up to 1 Medical Knowledge MOC point in the American Board of Internal Medicine’s (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.

Please note, this program has been specifically designed for the following ABIM specialty: medical oncology.

Personal information and data sharing: Research To Practice aggregates deidentified user data for program-use analysis, program development, activity planning and site improvement. We may provide aggregate and deidentified data to third parties, including commercial supporters. We do not share or sell personally identifiable information to any unaffiliated third parties or commercial supporters. Please see our privacy policy at ResearchToPractice.com/Privacy-Policy for more information. For those clinicians wishing to receive ABIM MOC credit for attending, you will receive an email after the event with instructions.

Content Validation and Disclosures
Research To Practice (RTP) is committed to providing its participants with high-quality, unbiased and state-of-the-art education and adheres to the ACCME’s Standards for Integrity and Independence in Accredited Continuing Education. Any individuals in a position to control the content of an accredited continuing education activity, including faculty, planners, reviewers and others, are required to disclose all relevant financial relationships with ineligible entities (commercial interests). All relevant conflicts of interest will have been mitigated prior to the commencement of each activity. In addition, all activity content is reviewed by RTP scientific staff and an external, independent physician reviewer for fair balance, scientific objectivity of studies referenced and patient care recommendations.

FACULTY — The following faculty reported relevant financial relationships with ineligible entities:

Dr JhaveriConsulting Agreements: AbbVie Inc, AstraZeneca Pharmaceuticals LP, Bristol-Myers Squibb Company, Daiichi Sankyo Inc, Eisai Inc, Genentech, a member of the Roche Group, Gilead Sciences Inc, Lilly, Loxo Oncology Inc, a wholly owned subsidiary of Eli Lilly & Company, Novartis, Pfizer Inc, Seagen Inc, Taiho Oncology Inc; Contracted Research: Gilead Sciences Inc, Merck, Puma Biotechnology Inc.

SERIES MODERATORDr Love is president and CEO of Research To Practice. Research To Practice receives funds in the form of educational grants to develop CME activities from the following companies: AbbVie Inc, Adaptive Biotechnologies Corporation, ADC Therapeutics, Agios Pharmaceuticals Inc, Alexion Pharmaceuticals, Amgen Inc, Array BioPharma Inc, a subsidiary of Pfizer Inc, Astellas, AstraZeneca Pharmaceuticals LP, Aveo Pharmaceuticals, Bayer HealthCare Pharmaceuticals, BeiGene Ltd, BeyondSpring Pharmaceuticals Inc, Blueprint Medicines, Boehringer Ingelheim Pharmaceuticals Inc, Bristol-Myers Squibb Company, Celgene Corporation, Clovis Oncology, Coherus BioSciences, CTI BioPharma Corp, Daiichi Sankyo Inc, Eisai Inc, Elevation Oncology Inc, EMD Serono Inc, Epizyme Inc, Exact Sciences Corporation, Exelixis Inc, Five Prime Therapeutics Inc, Foundation Medicine, G1 Therapeutics Inc, Genentech, a member of the Roche Group, Genmab, Gilead Sciences Inc, Grail Inc, GSK, Halozyme Inc, Helsinn Healthcare SA, ImmunoGen Inc, Incyte Corporation, Ipsen Biopharmaceuticals Inc, Janssen Biotech Inc, administered by Janssen Scientific Affairs LLC, Jazz Pharmaceuticals Inc, Karyopharm Therapeutics, Kite, A Gilead Company, Kronos Bio Inc, Lilly, Loxo Oncology Inc, a wholly owned subsidiary of Eli Lilly & Company, MEI Pharma Inc, Merck, Mersana Therapeutics Inc, Mirati Therapeutics Inc, Natera Inc, Novartis, Novartis Pharmaceuticals Corporation on behalf of Advanced Accelerator Applications, Novocure Inc, Oncopeptides, Pfizer Inc, Pharmacyclics LLC, an AbbVie Company, Puma Biotechnology Inc, Regeneron Pharmaceuticals Inc, Sanofi, Seagen Inc, Servier Pharmaceuticals LLC, SpringWorks Therapeutics Inc, Sumitomo Dainippon Pharma Oncology Inc, Taiho Oncology Inc, Takeda Pharmaceuticals USA Inc, TerSera Therapeutics LLC, Tesaro, A GSK Company, TG Therapeutics Inc, Turning Point Therapeutics Inc, Verastem Inc and Zymeworks Inc.

RESEARCH TO PRACTICE CME PLANNING COMMITTEE MEMBERS, STAFF AND REVIEWERS — Planners, scientific staff and independent reviewers for Research To Practice have no relevant conflicts of interest to disclose.

Supporters
These activities are supported by educational grants from AstraZeneca Pharmaceuticals LP, Exact Sciences Corporation, Sanofi, and TerSera Therapeutics LLC.